MultiStem is an allogeneic bone marrow-derived adherent adult stem cell product that has shown efficacy in preclinical models of acute myocardial infarction (AMI). In this phase I clinical trial in patients with first ST-elevation-myocardial infarction (STEMI), we combine first-in-man delivery of MultiStem with a first-in-coronary adventitial delivery system to determine the effects of this system on left ventricular function at 4 months after AMI.
S tem cell delivery in the peri-infarct period after reestablishment of antegrade flow has been under investigation for almost a decade. 1, 2 Significant advances have been made in our understanding of the molecular mechanisms associated with preservation of cardiac myocytes and optimization of ventricular remodeling by stem cells. [3] [4] [5] [6] Although the field has made significant progress, many questions in the funda-mental science and clinical application of stem cells in patients with acute myocardial infarction (AMI) remain. Arguably, 2 important unresolved clinical questions focus on identifying optimal cell populations and method(s) of administration.
The vast majority of clinical studies in patients with AMI to date has used autologous, bone marrow-derived stem cells and has demonstrated important safety and efficacy effects. 7, 8 Although autologous bone marrow-derived cells are appealing in important respects, logistical and biological limitations leave them as questionable as clinically applicable agents. Bone marrow aspiration (or induced mobilization) and cell selection add additional steps to the procurement process. Moreover, the number and potency of autologous cells are known to vary among patients and to decline in response to age and disease. 9 -11 Although the microenvironment of early postinfarction tissue is believed unfavorable to the function of progenitor cells, early administration, which more closely resembles the preclinical model, remains an unproven goal because there appears to be a maturation process of the marrow as a function of time after AMI. 7 The strategy of stem cell delivery at the time of primary percutaneous coronary intervention (PCI) thus is not feasible with most autologous sources.
The majority of studies in AMI have used intracoronary infusion down the infarct-related vessel as the means to deliver the stem cells, 7, 12 playing on well-defined homing factors present during the peri-infarct period 13 to drive cells across vessel walls in their recruitment to the heart. However, atherosclerosis, the very process underlying the clinical condition, may limit and affect the microvasculature, impeding stem cell entry into the myocardium. This too may explain the limited magnitude of effect observed in clinical trials to date.
MultiStem is an allogeneic bone marrow-derived stem cell product that is nonimmunogeneic and can suppress activated T-cell proliferation and has anti-inflammatory and angiogenic properties as well. These cells are based on multipotent adult progenitor cell that have trilineage differentiation potential. 14 In the acute postinfarction model, MultiStem decreases infarct size and improves left ventricular function. [15] [16] [17] [18] By combining MultiStem and a microneedle adventitial delivery system in a porcine model of AMI, we demonstrated significant improvements in cardiac function at 30 and 90 days after myocardial injury. 16 Using this as the basis for clinical study, we conducted a multicenter phase I trial of the effects of adventitial delivery of MultiStem 2 to 5 days after primary PCI, and herein report its findings.
Methods

Trial Design
The trial was a multicenter phase I, open-label, dose-escalation study with a registry control arm study (URL: http://www.clinicaltrials. gov. Unique identifier: NCT00677222). This was a first-in-man study to assess the safety and feasibility of MultiStem (Athersys, Inc, Cleveland, OH) administration through a microneedle catheter (Cricket, MercatorMedSystems, Inc, San Leandro, CA) in patients between 2 and 5 days after ST-segment elevation-myocardial infarction (STEMI). Three treatment cohorts (20 million, 50 million, and 100 million cells) and 1 medical cohort of patients were enrolled at 7 centers.
Patient Population
Patients eligible for this trial had a first episode of acute coronary syndrome resulting in myocardial damage that presented as STEMI. They underwent primary PCI with resulting Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow and left ventricular ejection fraction of Յ45% as assessed by contrast left ventriculography or echocardiography within 12 hours of the intervention. Patients had to be hemodynamically stable, without mechanical complications of AMI or indications for further coronary revascularization, to be eligible for enrollment. Patients who consented during times when MultiStem was not available (protocol-mandated 7-day period between successively dosed patients and 30-day period between treatment cohorts) were assigned to the registry arm (medical controls). The trial was conducted in compliance with current Good Clinical Practice standards and in accordance with the principles set forth under the Declaration of Helsinki (1989). Institutional review board approvals of the treatment protocol were obtained at all centers before the initiation of patient enrollment. All patients entering the trial agreed to and signed an institutional review board-approved statement of informed consent.
A total of 30 patients were screened for the trial, of which 25 were enrolled. Nineteen patients were treated with MultiStem (20 million cells, nϭ6; 50 million cells, nϭ7; 100 million cells, nϭ6) and 6 were followed in the registry control arm. The Data Safety and Monitoring Committee approved escalation to each dosing cohort. Patient enrollment occurred between September 2008 and February 2010.
Cell Preparation and Administration
MultiStem was derived from a single donor bone marrow aspirate, processed according to proprietary methods, cryopreserved in 10% DMSO, 5% human serum albumin, and 85% Plasma-Lyte A (Baxter) and reconstituted for administration within 12 hours of the study intervention. Nonionic contrast medium was added to a final preparation consisting of 20 or 25ϫ10 6 cells/mL in excipient (Plasma-Lyte A [Baxter] with DMSO and HSA Ͻ2% each) and 20% radiocontrast. Exposure to contrast agent and passage through the microneedle catheter has no significant effects on the viability of MultiStem or its ability to secrete vascular endothelial growth factor (VEGF). 16 The microneedle catheter is a 510(k)-approved intravascular device for infusion of diagnostic and therapeutic agents the perivascular area of the vessel wall. The needle has an outer diameter of 130 m and is 0.9 mm in length that allows it to extend beyond the external elastic lamina of blood vessels, directly into perivascular tissues on balloon inflation. Experience with an earlier iteration of the device has been reported. 19 Coronary angiography was performed to confirm patency of the infarct-related artery and to identify suitable sites for study injection(s), which were required to be in vessels of 2.5-3.0 mm in diameter (either distal or proximal to the stent) and free of significant stenoses. Positioning the microneedle in the periadventitia requires full balloon inflation in size-matched segments, generally in the infarct-related artery or a branch. This leads to stoppage of distal flow for an interval of 1-2 minutes during each injection. The number of injections was predetermined according to dosing cohort: a single injection of 1 mL of 20ϫ10 6 MultiStem for the 20 million cohort, a single injection of 2 mL of 25ϫ10 6 /mL MultiStem for the 50 million cohort, and 2 injections of 2 mL of 25ϫ10 6 /mL MultiStem for the 100 million cohort. Each injection of 1 or 2 mL was confirmed by a perivascular blush, characteristic of the admixture of MultiStem and radiocontrast. Intraprocedural heparin was administered to achieve an activated clotting time of Ն250 seconds; 
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Patient Assessment
Within 24 hours of study intervention (or between days 2 and 5 for the registry control patients), baseline (day 0) clinical status and laboratory assessments were taken, including serum chemistries, complete blood count, creatine kinase (CK)-MB, troponin, VEGF, allogeneic antibody, mixed lymphocyte reaction (MLR), CD34 counts (at selected clinical sites), and echocardiography. Within 24 hours of cell delivery and at day 7, month 1, and month 4, some or all (according to protocol) of these assessments were repeated. Allogeneic antibody detection, MLR assay, and VEGF analysis (see Online Tables I and II 
Echocardiography
Echocardiographic measurements were taken within 24 hours before cell administration (baseline), at day 7, month 1, and month 4, and analysis of end-systolic volume, end-diastolic volume, ejection fraction (EF), and stroke volume were made by blinded observers at the Echo Core Laboratory. A limited echocardiogram was performed within the first 6 hours after MultiStem injection to examine for the presence of pericardial effusion.
Statistics
This study was not powered for clinical outcomes, and data are presented as meanϮSD or SEM where indicated. Demographic data are recorded in tabular form and group comparisons made by ANOVA and post hoc analysis with Bonferroni correction was applied when appropriate. The numbers of safety end points (infusional and allergic toxicity, study procedure-related events, major adverse cardiovascular events) were compared by treatment group. Absolute and changes in measures of EF and stroke volume were analyzed by ANOVA and Dunnett post hoc analysis used to compare to the registry control group with efficacy end points at 4 months. All pairwise comparison were analyzed using the Student t test (2-tailed, paired). All probability values are 2-sided, and statistical significance was set at PϽ0.05.
Results
Patient Profile
Baseline demographic and postintervention characteristics of patients enrolled in the study are presented in ␤-blocker 6 (100%) 6 (100%) 6 (86%) 6 (100%) ACE inhibitor or ARB 4 (67%) 6 (100%) 7 (100%) 6 (100%) Statin 6 (100%) 6 (100%) 6 (86%) 5 (83%)
Aldosterone antagonist 1 (17%) 0 (0%) 1 (14%) 0 (0%) Table 1 depict core laboratory measurements taken within 24 hours of MultiStem injection rather than qualifying EF values. Core laboratory echo measurements were not available to the treating physician before study intervention. Figure 1 shows sequential images from a representative study injection. The arrows depict the balloon catheter in the preinjection image and the growing plume of MultiStem mixed with contrast in all other images. Compared with preinjection, the completed image is without evidence of dissection or perforation after removal of the microneedle catheter. Injection sites were distal to the stent in 18 patients and proximal in 1 patient. In all 3 treatment groups, there were no changes in coronary anatomy or TIMI grade 3 flow after injections. Early (6 hours) after the procedure, clinical status (including vital signs) and echocardiograms were unremarkable in all treated patients. A trivial pericardial effusion was observed in 1 patient (50 million group) within 6 hours after cell delivery. At 13.5 hours after cell injection, a second patient (20 million group) had a myocardial rupture, resulting in death. This patient, a 71-year-old woman who underwent study intervention on day 4 after a large anteroseptal MI (peak CK-MB, 615 ng/mL; baseline EF, 40%), had been clinically stable before this sudden event. An echocardiogram at 1 hour after cell injection was without effusion or change in wall motion. Postmortem findings were with hemorrhagic infarction and free wall rupture of the anteroapical wall and without evidence of coronary perforation. This event was deemed to be unrelated to MultiStem injection by the study's Safety Committee. One patient had a brief episode of angina within hours after cell injection and another had asymptomatic atrial fibrillation at 8 hours, subsequently treated with electroconversion. No other patient had significant changes in vital signs, clinical status, serum chemistries, or blood counts (data not shown) over the 24 hours after the injection period. At 18 hours after injection, serum CK-MB did not rise in any patient compared with preinjection levels (Table 1) , and by day 7 were normal in all injected patients.
Safety of Adventitial Delivery of MultiStem
Other clinical events in the treatment group occurred within the first week: 1 at 2 days in a patient reported to have a small pericardial effusion based on CT scan for suspected pulmonary embolism (negative), subsequently excluded by echocardiography, and another at 5 days in a patient who had a maculopapular rash, which resolved with alterations in concomitant medications.
Between 1 week and 4 months, there were no major adverse cardiovascular events. Holter monitoring was performed at day 7 and month 1; the results are shown in Table  2 . The Holter findings are grouped into categories reflecting potentially clinically important rhythm abnormalities. There were no significant differences between the treatment group and control for any of the categories listed at either of the time points or for the category "any arrhythmia." There was a trend noted for lower incidence of tachycardia in the pooled treatment group at both time points. The number of each of the protocol defined major adverse cardiac events observed are listed in Table 3 .
Immunologic Response
MultiStem is an allogeneic stem cell product. Both humoral and cellular responses were examined at baseline, month 1, Tables I and II for HLA and MLR results,  respectively) .
Cardiac Function
The data in Figure 2 depict EF at the baseline and month 4 in each of the patients enrolled in the trial. The solid line represents those patients with core laboratory-determined EFs Յ45% on the day of treatment, whereas the dashed lines are those patients with EF Ͼ45% on the day of treatment as later determined by the core laboratory. As seen in Figure 3A , there is a 4.1% absolute increase in EF in those patients who received 20 million cells and a significant 8.7% absolute increase in EF from baseline in those patients who received 50 million cells (PϽ0.05). Interestingly, in this analysis there was no significant improvement in patients who received 100 million cells. Many studies have demonstrated a lack of benefit with cell therapy in the setting of preserved left ventricular function. 7, 12 For this reason, we prespecified that enrollment would be restricted to patients with EF Յ45%. There was a total of 13 patients enrolled (10 dosed) with EF Յ45% at baseline as determined by the core laboratory. Figure 3B only includes those patients with baseline EF Յ45%. In this analysis, we observe similar effects between the 50 million (12.6% absolute increase) and 100 million (10.0% absolute increase) doses and a statistically significant increase in EF at month 4 in the combined 50 million and 100 million doses compared with those patients in the registry control (PϽ0.05).
We quantified left ventricular stroke volume by integrating the velocity time interval across the aortic valve. Consistent with our findings of improved EF, the left ventricular stroke volume was increased in both the 50 million (ϩ14.6 mL) and 100 million (ϩ7.9 mL) dose groups, whereas a decrease in stroke volume was observed in the registry control (Ϫ4.3 mL) Table 3 and 20 million (Ϫ3.6 mL) dose group ( Figure 4A ). Further analysis of patients whose baseline EF Յ45% ( Figure 4B ) revealed that the 50 million dose group had a significant improvement in stroke volume (ϩ25.4 mL) compared with the registry control (Ϫ12.5 mL) (PϽ0.01). Combining both the 50 million and 100 million (ϩ8.4 mL) dose groups compared with the registry control group also was observed to be significant (PϽ0.01).
. Number of Protocol-Defined Major Adverse Cardiac Events Through 4 Months After Acute Myocardial Infarction
Discussion
Stem cell-based repair of acute ischemic myocardial injury offers the potential to decrease infarct size, modulate ventricular remodeling, and improve outcomes. 7, 8 Clinical studies in the STEMI patient have focused on autologous bone marrow-derived stem cells and intracoronary infusion of these cells down the infarct related vessel. 7, 20 This approach appears to be optimal 4 to 7 days after primary PCI due to the apparent need for bone marrow maturation, 7 requires the time for harvesting and processing of the bone marrow aspirate, and to date the effects seen do not rival the magnitude of effect seen in preclinical models. 7, 8 In this study we have combined a novel allogeneic off-theshelf bone marrow-derived cell product with a novel adventitial delivery system. This combination allows cell delivery at any time from the time of primary PCI. In this study, we chose to deliver MultiStem 2-5 days (mean time was 3.3 days) after primary PCI so that we could determine if adventitial delivery of MultiStem resulted in myocardial damage through the quantification of changes in CK-MB and troponin. Analysis of these cardiac enzymes demonstrated that the delivery of MultiStem by using a transarterial catheter into the adventitial layer was safe.
Furthermore, we were able to demonstrate increases in EF in the patients treated with 50 million and 100 million MultiStem with delivery on average 3.3 days after primary PCI, a time point significantly sooner than determined to be optimal in previous clinical trials. 7 Although our findings should be interpreted in the setting of a phase I study with limited power, the data generated from this study support the hypothesis that our approach is applicable to patients with significant left ventricular dysfunction and have led us to several important, preliminary conclusions.
First, the administration of MultiStem into the coronary adventitia early after STEMI did not lead to demonstrable negative effects. The structural integrity of epicardial coronary vessels and angiographic signs of microvascular flow were preserved immediately after injection. Before our study, the microneedle catheter had not been applied in diseased coronary vasculature, either preclinically or clinically. Consequently, data and observations from this phase 1 study do not permit conclusions to be made regarding the device's efficiency as a tool for biologics administration or its longterm safety profile in patients. We have addressed cell biodistribution in a recent porcine study. 16 Symptoms and signs of early reinfarction were absent in all subjects, without rise in myocardial biomarkers during the 18-hour observation period after injection, and the frequency of arrhythmias on ambulatory monitoring was similar in treatment and nontreatment groups. As noted, the myocardial rupture was judged to be unrelated to the study procedure. As to the potential for inducing immunologic reactions, no patient mounted humoral or cellular responses characteristic of such processes, consistent with findings from preclinical studies. 16, 21 Other adverse events observed in this study were infrequent and their relationship to the investigative procedure were deemed unlikely by the site Principal Investigators and the Data Safety Monitoring Committee.
Second, increases in EF at 4 months were observed in patients with relatively early (mean, 3.3 days) administration of MultiStem, most notably in patients with core baseline EF under 45% and treated with 50 million and 100 million cells. Of note, the relative improvement in EF observed in this phase I trial is strikingly similar to that seen in a porcine AMI model 16 (35% versus 38%, respectively). As previously stated, this time frame for cell delivery after PCI is sooner than determined to be optimal in previous clinical trials 7 and suggests that our approach could easily be applied immediately after primary PCI. The ability to detect relationships between time or dose and left ventricular function is outside the statistical power of our study.
Whereas autologous bone marrow-derived stem cell therapy has been shown to be efficacious, the magnitude of the effect reported for clinical populations is significantly less than that observed in preclinical models. It is interesting to compare the loss of efficacy in the translation of MSC and MultiStem from preclinical studies to human studies. The efficacy of the intravenous delivery of MSC on EF went from a relative increase of Ϸ80% in rats 3 to 10% at the high dose of MSC in the phase I trial. 22 For MultiStem, the improvement in EF in a porcine AMI model was Ϸ38%, 16 which is strikingly similar to the Ϸ35% we observed in the combined 50 million and 100 million groups in this phase I trial. Although the consistency in effect observed for MultiStem treatment in the porcine model and the phase I study could be solely due to the therapeutic benefits of MultiStem, it is equally possible that the delivery method contributed to the consistency in results. In this trial and in our porcine AMI model, we delivered MultiStem to the adventitia avoiding the atherosclerotic intima of the diseased coronaries. In contrast, the efficiency of delivery of MSC to the myocardium through intravenous infusion (and for that matter, autologous bone marrow through infusion down the infarct related vessel) into patients with coronary artery disease could have been reduced or inhibited compared with that observed in rodents and large animals that have nondiseased arteries.
The mechanisms of action of the benefits associated with MultiStem are still under investigation. Several potential benefits have been demonstrated including inhibition of the inflammatory response, inhibition of cardiac myocyte death, 18 and induction of angiogenesis. 15, 17 Importantly, Mul-tiStem studies to date have not demonstrated generation of new cardiac myocytes or significant long-term cell engraftment, even with MultiStem's substantial differentiation capacity. 17 These findings combined with the improvements in cardiac function observed in this study further demonstrate the important therapeutic potential of the modulation of the paracrine factor milieu after adult stem cells engraftment in the injured myocardium.
Conclusion
In this study, the delivery of MultiStem to the myocardium in patients with recent STEMI was well tolerated and appears safe. In patients who exhibited significant myocardial damage, the delivery of Ն50 million MultiStem resulted in improved EF and stroke volume 4 months later. These findings validate the potential of a system for delivery of adult stem cells at any time after primary PCI and support further development of MultiStem in patients with acute coronary syndrome.
